Provention Bio, Inc. is a newly-formed clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease.
Our “predict and prevent” therapeutic model is focused on developing drugs that intervene before the target disease begins, re-appears or progresses. By way of this approach, we believe Provention is well-positioned to be a leader in a new biopharmaceutical category centered on interception of disease and offers the potential of reducing the high morbidity, mortality and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, and ulcerative colitis, as well as emerging viral infections.
Provention has been carefully conceived and positioned to be at the forefront of this pioneering new paradigm in medicine. We believe Provention’s business model, coupled with our expertise in translational medicine, immunology and the design and execution of rapid go/no-go clinical trials, will enable us to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.
Provention Bio - Intercepting and preventing immune-mediated disease before it’s too late.